Serotonin 

 448 Products   448 Products   1070 Diseases   113911 News 


«12...4849505152535455565758...11171118»
  • ||||||||||  lithium carbonate ER / Generic mfg., clozapine / Generic mfg.
    Pseudospecific Versus Transdiagnostic Symptom Targeting in Pharmacotherapy Trials: Agitation, Attention, Anhedonia, and Mood Instability (Salon 2) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_442;    
    For example, are the antisuicide properties of clozapine or lithium generalizable to conditions beyond schizophrenia or bipolar disorder, respectively?...Controversies surrounding the term "pseudospecificity" itself as a valid or useful construct will be addressed, alongside practical implications for clinical trial design, clinical generalizability, and regulatory agency approval of therapeutic agents. Learning Objectives 1) To understand controversies regarding the concept of pseudospecificity when identifying pharmacodynamic claims about drug efficacy; 2) To understand ways in which "narrow" drug target symptoms -- notably, hostility, attention, anhedonia, or mood instability -- represent transdiagnostic phenomena or pseudospecific features that are only responsive to treatments aimed more broadly at a distinct overarching psychiatric condition.
  • ||||||||||  clozapine / Generic mfg.
    Early Results from the NIMH-Funded Early Psychosis Intervention Network (EPINET) (Poinciana 3-4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_440;    
    Long-acting injectable antipsychotics (LAIs) and clozapine are the most effective medications in preventing relapse and hospitalization...Learning Objectives To familiarize attendees with current evidenced based pharmacologic treatment for first episode and early phase schizophrenia. To review obstacles and challenges in implementing research findings into clinical practice in the context of coordinated specialty care.
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Clinical Psychopharmacology of Bipolar Disorder: Selected Studies (Salon 3) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_435;    
    The meta-analytically pooled data found a highly significant, 76.8% reduction of risk with lithium treatment, with similar results for six trials involving suicides. Clinical Psychopharmacology of Bipolar Disorder: Selected Studies Clinical Psychopharmacology of Bipolar Disorder: Selected Studies Submission ID 3005418
  • ||||||||||  Zurzuvae (zuranolone) / Sage Therapeutics, Biogen
    Understanding Drug Safety Decisions as New Therapies Emerge: The Importance of Perspective (Salon 2) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_425;    
    For schizophrenia, there were two occasions with substantial delays in recognizing safety risks of antipsychotics: first for the 20 year delay in TD awareness after the antipsychotics first appeared in the 1960s, and later for medical risks associated with the arrival of clozapine and other atypical antipsychotics...The timing of this panel is relevant today given the number of emerging agents with very different safety profiles than existing options including affective disorders (e.g., zuranolone), schizophrenia (e.g., muscarinic agonists) and PTSD (e.g., psychedelics)...Understand differences in approach to safety and risk of new and emerging therapies is based historical examples in other psychiatric therapies that were new and evolved over time and put in context with risk bias literature in complex situations with limited information and competing priorities. Literary
  • ||||||||||  olanzapine / Generic mfg.
    Bridging the Gap Between Body and Brain  (Poinciana 3-4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_423;    
    Kyle Burghardt (Wayne State University, USA) will describe the role of epigenomics in skeletal muscle insulin sensitivity by surveying the skeletal muscle DNA methylome response in a fasting versus insulin-stimulated state in olanzapine-treated versus placebo-treated healthy volunteers...Appreciate the bidirectional relationship between mental and physical health 2. Learn how this bidirectionality opens up a therapeutic opportunity to improve both physical and mental health Literary
  • ||||||||||  Interventional Options for Treatment-Resistant Depression (TRD): Lessons from ASCERTAIN-TRD and ELEKT-D Studies (Poinciana 1-2) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_422;    
    Therefore, clinicians may often need to choose interventional treatments such as repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), or intravenous (IV) ketamine...The ASCERTAIN-TRD study compared augmentation with either aripiprazole or rTMS to switch to another antidepressant (either venlafaxine or duloxetine) among outpatients with TRD...Identify potential clinical markers that can be used to inform selection between pharmacological and neuromodulation interventions. Literary
  • ||||||||||  sertraline / Generic mfg., bupropion / Generic mfg.
    Reward-Related Behavioral and Neuroimaging Markers Predicting Treatment Response in Major Depression (Poinciana 3-4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_405;    
    Preliminary (unpublished) findings from this prospective clinical trial will be presented. Learning Objectives 1) Understand how behavioral and imaging markers can be used to predict treatment response 2) Evaluate the role of the brain reward system in antidepressant responses.
  • ||||||||||  Spravato (esketamine intranasal) / J&J
    Comparative Effectiveness of Intravenous Racemic Ketamine and Intranasal Esketamine in Adults with Treatment Resistant Depression (Poinciana 1-2) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_398;    
    Effectiveness, tolerability and acceptability will be discussed in what is the largest RWE effectiveness comparison of these aforementioned treatment options. Learning Objectives 1) To discuss a rationale for real world evidence (RWE) comparing IV racemic ketamine to IN esketamine 2) To compare the effectiveness of IV racemic ketamine and IN esketamine in adults with TRD in two real-world international samples
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Clinical Psychopharmacology of Bipolar Disorder: Selected Studies (Salon 3) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_344;    
    More recently, we pooled data from nine randomized, controlled trials in which suicidal acts were noted among adverse outcomes (not as a primary study outcome, which, other than the notable exception of the InterSePT trial of clozapine vs. olanzapine with schizophrenia, is very rare in the therapeutics of suicide prevention). The meta-analytically pooled data found a highly significant, 76.8% reduction of risk with lithium treatment, with similar results for six trials involving suicides.
  • ||||||||||  nortriptyline / Generic mfg., escitalopram / Generic mfg.
    A Clinician's Perspective on Immune Mechanisms of Depression (Salon 1) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_329;    
    2. Discuss the potential utility of pro-inflammatory markers in guiding antidepressant treatment selection.
  • ||||||||||  clozapine / Generic mfg.
    The Role of Patient Voice in New Drug Evaluations: Advocacy Perspectives (Salon 2) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_293;    
    These were barriers to clozapine caused by problems in the current REMS program, and the need to balance safety reviews with the need to have more effective medications available...present on the role of disease-specific advocacy organizations, with a disease focus providing greater opportunities for in-depth advocacy in key areas of unmet needs 2. discuss collaboration with the FDA in partnering on an advocacy-initiated Patient-Focused Drug Development meeting
  • ||||||||||  haloperidol / Generic mfg.
    Drug Safety Decisions Are Not Always Rational: A Kahneman Perspective of Cognitive and Emotional Biases (Salon 2) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_291;    
    One illustration is the apparent complacency in which potentially life-threatening adverse events from using haloperidol IM in ER settings, such as malignant hyperthermia, NMS or laryngospasm...2. The panel will address some key points of risk literature on cognitive biases that might influence decisions on safety risks for emerging treatments especially when their safety profiles are fundamentally different than those therapies currently available.
  • ||||||||||  armodafinil / Generic mfg.
    Modafinil / Armodafinil in Bipolar Disorder: Lesson Learned, Roadmap Forward (Salon 1) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_284;    
    Better understand design challenges in a non-mood stabilizer being investigated for bipolar depression 2. Appreciate subtypes of bipolar depression that may prove useful for subsequent narrower investigation Literature
  • ||||||||||  venlafaxine / Generic mfg., aripiprazole / Generic mfg., duloxetine / Generic mfg.
    Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-Responders with Treatment Resistant Depression (ASCERTAIN-TRD): Report of Primary Outcome. (Poinciana 1-2) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_273;    
    Learning Objectives 1) By the end of this session the audience will have a better understanding of the relative effectiveness of rTMS augmentation, aripiprazole augmentation versus switching to venlafaxine/duloxetine in TRD on clinician-rated symptoms of depression. 2) By the end of this session the audience will have a better understanding of the relative effectiveness of rTMS augmentation, aripiprazole augmentation versus switching to venlafaxine/duloxetine in TRD on patient-rated symptoms of depression.
  • ||||||||||  methadone / Generic mfg.
    Oxybutynin is Effective on Methadone- Induced Hyperhidrosis treatment: A Case Report (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_258;    
    Biperiden, is an anticholinergic medication which has been used to treat methadone-induced diaphoresis and sweating in 3 cases , while Al-Adwani described the successful management of opioid-induced hyperhidrosis by an antihis tamine, desloratidine, and most recent case who was treated successfully with Oxybutynin 5 mg QID for methadone-induced hyperhidrosis reported in 2017...This study supports the prior case report finding about treatment of methadone- induced hyperhidrosis with oxybutynin. The present case proposes that oxybutynin 5 mg oral tablet twice daily) can be very effective and merits consideration in patients with methadone-induced hyperhidrosis and help methadone clinic and health care providers to diagnose and treat one of the less recognized adverse effects of methadone.
  • ||||||||||  sertraline / Generic mfg., fluoxetine / Generic mfg.
    Fluoxetine and Sertraline Inhibit Height Growth During Puberty (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_230;    
    Future studies should examine whether adult height and body composition are impacted. Learning Objectives To learn about potential effect of SSRIs on height growth in children and adolescents.
  • ||||||||||  Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
    PET/CT Study of Dopamine Transporter (DAT) Binding with the Novel Triple Reuptake Inhibitor Toludesvenlafaxine in Rats and Humans (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_229;    
    These results represent the first to confirm the binding of toludesvenlafaxine to DAT in both rats and humans using PET/CT, and its elevation of brain DA level, which may help understand the unique pharmacological and functional effects of triple reuptake inhibitors such as toludesvenlafaxine. Learning Objectives PoM exploratory clinical research by combining PET/CT and microdialysis; to assess Dopamine Transporter occupancy in the Healthy Adult Brain Using 11C-CFT PET
  • ||||||||||  ulotaront (SEP-363856) / Sumitomo Pharma, Otsuka, PsychoGenics
    Ulotaront Delays Gastric Emptying Time in Schizophrenia Patients with Metabolic Syndrome (NCT05402111) (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_227;    
    P1
    Patients were required to maintain a stable dose and regimen for one of 4 antipsychotics as treatment for schizophrenia at the time of screening (risperidone, olanzapine, quetiapine, or aripiprazole). : Following a single-dose of 150 mg ulotaront, gastric emptying was delayed (T1/2 = 145
  • ||||||||||  Aristada Initio (aripiprazole lauroxil nanocrystal dispersion) / Alkermes
    Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_219;    
    Learning Objectives 1) At the conclusion of this presentation, attendees will understand the treatment patterns observed over up to 6 months after initiation of aripiprazole lauroxil (AL) initiated using a one-time injection of a Nanocrystal Dispersion formulation of AL (ALNCD). 2) At the conclusion of this presentation, attendees will be able to describe the changes in 1 healthcare resource utilization observed from 6-month baseline to 6-month follow-up after initiating AL using ALNCD
  • ||||||||||  Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
    Early Improvement of Symptoms in Bipolar I Depression Predicts Functional Remission and Recovery: A Post Hoc Analysis (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_211;    
    P2
    In patients with bipolar I depression who were treated with cariprazine 1.5 mg/d, early improvement in depression, anxiety, and anhedonia symptom domains were all predictive of eventual functional remission and recovery, with early improvement in anhedonia being the most robust predictor. Learning Objectives
  • ||||||||||  Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Caplyta (lumateperone) - Intra / Cellular Therapies
    Do Second Generation Antipsychotics Protect Against the Emergence of (Hypo)mania in Depressed Patients with Mixed Features? (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_192;    
    Given the more general risk of a (hypo)manic switch, we wondered if medications proven effective in treating bipolar depression might be protective against such a switch. The results of the present analysis suggest that the second generation antipsychotics that are effective in treating bipolar depression protect against a (hypo)manic switch in patients with mixed features.
  • ||||||||||  Tonmya (cyclobenzaprine SL) / Tonix
    Optimizing Acute Stress Reaction (ASR) Interventions with TNX-102 SL (Sublingual Cyclobenzaprine HCl)  (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_191;    
    TNX-102 SL, a potential first-line treatment for FM and PTSD, is expected to provide similar therapeutic benefits and favorable tolerability for the treatment of ASR/ASD/PTSD, pain, and associated neurocognitive dysfunction. The results may ultimately provide military personnel, veterans, and civilians with a new treatment option that, when administered in the early aftermath of a traumatic event, improves recovery, job performance, and quality of life.